Top ▲

Lupus nephritis

Disease ID:1055
Name:Lupus nephritis
Associated with:1 target
1 immuno-relevant ligand




Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved drug for LN, as an adjunct to a background immunosuppressive therapy regimen
Clinical Use: Voclosporin was advanced to clinical evaluation for autoimmune diseases and the prevention of organ graft rejection. The FDA approved voclosporin (Lupkynis®) in January 2021, as an adjunctive treatment for active lupus nephritis, to be used in combination with a background immunosuppressive therapy. In the EU voclosporin was granted orphan designation (December 2012) as a treatment for non-infectious uveitis. | View clinical data
Bioactivity Comments: Voclosporin binds cyclophilin A (a.k.a. peptidylprolyl isomerase A) [1]. | View biological activity


Show »

1. Kuglstatter A, Mueller F, Kusznir E, Gsell B, Stihle M, Thoma R, Benz J, Aspeslet L, Freitag D, Hennig M. (2011) Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr, 67 (Pt 2): 119-23. [PMID:21245533]